In the era of precision medicine, the controllability and targeting efficiency of drug delivery systems play a crucial role in determining therapeutic outcomes. Among various nanomaterials, gold nanoparticles (AuNPs) have emerged as a powerful platform for cancer therapy, gene delivery, imaging diagnostics, and vaccine development due to their outstanding biocompatibility, tunable surface chemistry, stability, and multifunctionality. However, the ability to precisely engineer gold nanoparticle size, surface properties, and targeting modifications remains a major challenge for clinical translation.
As a global leader in nanomedicine and drug delivery, Litchlab has developed an advanced surface engineering platform for highly controlled gold nanoparticle modification, enabling efficient, precise, and safe nanodrug delivery. By integrating gold nanoparticle preparation, surface functionalization, and targeted delivery optimization, Litchlab is driving innovations in RNA therapeutics, antibody-drug conjugates (ADCs), photothermal therapy (PTT), and cancer immunotherapy.
Key Advantages of Gold Nanoparticles in Drug Delivery
Gold nanoparticles (AuNPs) offer unique advantages in drug delivery due to their high-density ligand conjugation capacity, tunable size, superior stability, and biocompatibility:
✔ Precise Targeting – Functionalization with antibodies, aptamers, and glycosylation ensures selective drug delivery, minimizing off-target toxicity.
✔ Enhanced Stability – Gold nanoparticles exhibit exceptional chemical stability and resistance to enzymatic degradation, improving RNA and protein drug stability.
✔ Efficient Cellular Uptake – Surface engineering (cationic/hydrophobic modifications) facilitates intracellular drug delivery, enhancing therapeutic efficacy.
✔ Multimodal Therapy – Combining photothermal therapy (PTT), photodynamic therapy (PDT), and immune modulation, gold nanoparticles enable synergistic cancer treatments.
✔ Stimuli-Responsive Release – pH, light, and temperature-triggered drug release strategies ensure on-demand drug activation in targeted tissues.
Litchlab’s Breakthroughs in Gold Nanoparticle Drug Delivery
Key Technology | Litchlab Solution | Applications |
Precise Gold Nanoparticle Size Control | Advanced microfluidic synthesis and supramolecular self-assembly, achieving highly uniform nanoparticles (10-100 nm) | Cancer therapy, gene delivery, imaging |
Surface Functionalization | Conjugation with antibodies, aptamers, PEG, and enzymatic modifications, enhancing targeting efficiency and stability | RNA therapeutics, ADCs, protein drug delivery |
pH-/Light-Responsive Drug Release | Tumor microenvironment-sensitive release (pH 6.5-6.8), maximizing local drug efficacy | Anticancer drugs, gene editing, PDT |
Dual-Drug Co-Delivery System | Electrostatic/covalent binding enables co-delivery of siRNA and small molecules for enhanced therapeutic synergy | RNAi therapy, mRNA vaccines, combination therapy |
Immune Modulation Functionalization | Macrophage-targeting modifications enhance tumor immune responses | PD-1/PD-L1 inhibitor delivery, CAR-T therapy |
Litchlab’s Gold Nanoparticle Drug Delivery Applications
✅ Gold Nanoparticle-Based Chemotherapy Enhancement:
Gold nanoparticles improve the targeted delivery of paclitaxel, doxorubicin, and other chemotherapeutic agents.
Microenvironment-responsive release (pH-triggered, enzyme-degradable) enhances efficacy while minimizing systemic toxicity.
✅ Gold Nanoparticles in Photothermal/Photodynamic Therapy (PTT/PDT):
Near-infrared (NIR) activation (808-980 nm) enables localized tumor heating, complementing chemotherapy and radiotherapy.
Conjugation with photosensitizers (e.g., ICG, ZnPc) enhances tumor cell destruction via photodynamic mechanisms.
✅ Gold Nanoparticle-Based Immunomodulation:
Functionalized with PD-1 monoclonal antibodies and T-cell activators, gold nanoparticles enhance cancer immunotherapy efficacy.
Targeting tumor-associated macrophages (TAMs) reduces immune suppression, improving anti-tumor immune responses.
✅ mRNA/siRNA Delivery:
Litchlab integrates cationic lipid-modified gold nanoparticles (AuNP-LNP) to enhance RNA stability and intracellular delivery.
Suitable for RNA interference (siRNA), gene editing (CRISPR/Cas9), and mRNA vaccine applications.
✅ CRISPR/Cas9 Gene Editing Delivery:
PEI-modified gold nanoparticles improve single-guide RNA (sgRNA) transport, increasing gene editing precision and reducing off-target effects.
Applications include genetic diseases, cancer gene editing, and neurodegenerative disease therapy.
Functionalized with protein antigens and CpG oligonucleotides, gold nanoparticles enhance vaccine immunogenicity and antigen presentation.
Applicable for personalized cancer vaccines and next-generation COVID-19/influenza vaccines.
✅ Personalized Immune Modulation:
Co-delivery of TLR agonists (e.g., R848) promotes dendritic cell maturation, enhancing immune responses.
Potential applications in cancer immunotherapy and autoimmune disease regulation.
Litchlab’s Gold Nanoparticle Drug Delivery Platform: Empowering Next-Generation Nanomedicines
Litchlab provides end-to-end solutions from laboratory research to GMP-scale production, accelerating the clinical translation of gold nanoparticle drug delivery systems.
Technology Module | Litchlab Solution |
Gold Nanoparticle Synthesis & Scalable Production | Microfluidic-assisted self-assembly, GMP-grade synthesis |
Customizable Targeting Modifications | Antibody, aptamer, and ligand conjugation for precision targeting |
Stimuli-Responsive Drug Release | pH, light, and temperature-triggered release mechanisms |
Stability Optimization | Enhancing RNA therapeutics and antibody drug stability |
Future Perspectives: Advancing Precision Medicine with Gold Nanoparticle Delivery
As nanotechnology, precision medicine, and targeted drug delivery continue to evolve, gold nanoparticles are emerging as a next-generation precision delivery platform. Litchlab’s highly controlled surface engineering technology is at the forefront of this revolution, enabling pharmaceutical companies to develop more efficient, safer nanomedicines and accelerate their clinical translation.
For more information, please feel free to contact us at:
E-Mail:RD2@Litchlab.com
